Regulatory agencies installed orphan drug regulations to stimulate research and development of new innovative treatments for life-threatening diseases with a low prevalence (rare diseases). We established a list of well-known food-related ingredients with clinical evidence for rare diseases in the open medical literature that obtained marketing authorization as an expensive “orphan drug”, protected by intellectual property (IP) rights. We show that these ingredients are part of an established practice of medicinal compounding—a form of point of care manufacturing. We argue that these ingredients should be considered as “pharmaceutical commons”, and that regulatory incentives for private companies and market protection mechanisms such as IP rights are not justified in this case.

Keywords: rare diseases, orphan drugs, compounded medication, intellectual property, drug research and development, open science, commons, point of care manufacturing

INTRODUCTION: ORPHAN DRUGS AND OWNERSHIP

Worldwide several so-called orphan drug regulations were installed by national agencies to promote research and development (R&D) of medicinal products and devices intended for the prevention, diagnosis and treatment of rare diseases. The European Union defines a drug as “orphan” if it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically and seriously debilitating condition affecting not more than five in 10,000 persons (European Medicines Agency, 2021a). Such a condition is called a “rare disease”. About 30 million people in the EU suffer from a rare disease (Ibid.). Authorization of orphan drugs is subject to European regulation, while pricing and reimbursement is done according to national legislation in the different EU Member States.

This resulted in the authorisation of several hundreds of orphan drugs mainly thanks to the incentives given by national agencies such as market exclusivity, centralized procedure and fee reductions (Huyard, 2009; Mikami, 2017). The main aim of this article is to show that several pharmaceutical ingredients used in orphan drugs are part of an established practice of medicinal compounding and should be considered as “pharmaceutical commons”. We argue that regulatory incentives for private companies and market protection mechanisms such as intellectual property rights are not justified in this case.

There are different ways in which orphan drugs are brought to the market. Over 200 orphan drugs are registered by the European Medicines Agency (EMA) so far, for an estimated total number of

Abbreviations: EMA, European Medicines Agency; EU, European Union; IP, Intellectual property; NA, not applicable; R&D, Research and Development; WHO, World Health Organization.
between 5,000 and 8,000 rare diseases (European Commission, 2021a). The discovery and development of innovative “new molecular entities” is the least common way. More often, existing drugs are repurposed, which involves lower R&D costs while companies may still benefit from intellectual property (IP) rights. Despite analyses that show the inefficiency today of intellectual property regimes for the drug discovery and development process (Bountra et al., 2017; Lezaun and Montgomery, 2015), ownership remains an issue that pharmaceutical companies cling to, claiming that IP rights are justified in view of the high costs in the drug discovery process (and the high attrition rate), and the ‘small market’ for orphan drugs. More and more analysts now defend the principles of open science, arguing that sharing data early on in the drug discovery process will reduce the duplication of research and investments, and that it will stimulate innovation rather than sticking to a very limited number of ‘promising molecules’ or ‘high impact indications’. Varying business models are proposed, with either limited IP rights or with other forms of ownership (such as non-profit organizations as the owners, see Davies et al., 2017). Extension of the principles of open science to the clinical evaluation of drug candidates and the creation of a system of incentives that would encourage pre-competitive IP-free research was proposed for a radical reconstruction of the drug discovery ecosystem (Bountra et al., 2017; Rubinstein et al., 2020).

Some argue, however, that many practices of sharing data tend to take place amongst a limited number of companies that are motivated by the prospect of obtaining IP rights in the future. In this case, it is not open science but rather a pooling of research data among select companies (excluding other companies or research institutes) in order to make drug discovery more efficient. The final objective is to obtain ownership nonetheless (Lezaun and Montgomery, 2015). When the first orphan drug regulations were established, mainly small and medium sized enterprises created the orphan drug market (e.g., Actelion, BioMarin, Genzyme, Shire, SoBi) but today big pharmaceutical industries take the lead (e.g., Bayer, Glaxosmithkline, Novartis, Pfizer, Sanofi).

**COMPOUNDED MEDICATION**

The above analyses and debates are important, but they overlook the practice of pharmaceutical compounding and “hospital exemption” which happens in (hospital) pharmacies, based on pharmacopeial rules, practical know-how and “registries” of clinical evidence. A great many effective treatments for rare diseases exist that are not based on the industrial process of drug discovery and regimes of intellectual property rights (Dooms et al., 2013; Dooms and Carvalho, 2018). Indeed, these compounds did not go first through the EMA for approval but, as they are mentioned in the European Pharmacopoeia¹, they are allowed by European legislation to be used and administered for helping patients. In some cases, hospital pharmacies also repurpose or reformulate existing drugs and dispense off-label. A number of compounds have been used by companies to obtain an EMA license, thereby turning a relatively cheap and openly available treatment into an expensive commercial product simply by registering it as an orphan drug with the EMA. (Busilvex, Chenodeoxycholic acid, Firdapse, Jorveza, Kolbam, Ledaga, Namuscla, Orphacol, Pedea, Peyona, Siklos, Trisenox, Verkazia, Wilzin). While new drugs need to show a significant benefit over existing ones, no comparisons are made with compounded medication. This problem is well-known and studies exist that compare the costs of compounding with the purchase price of registered orphan drugs (Simoens et al., 2011). When the cheaper compounded alternatives still exist, some countries (like Belgium for example) refuse to reimburse the more expensive product to patients. In other countries (like France and Germany) all medication for rare diseases is fully reimbursed (Picavet et al., 2011; Dooms et al., 2013). In both cases, the situation is not cost-effective, as reimbursement leads to unnecessary costs for public health, and non-reimbursement decreases the sales and profits for commercial products. It is interesting and necessary to look closer into the actual compounds and the practice of compounding, as this provides pathways to think differently about ownership, open science and public-private relationships.

**A LIST OF COMMON INGREDIENTS: METHODS AND RESULTS**

The data in Table 1 were collected through the Union Register of Orphan Medicinal Products (European Commission, 2021a), WHO Collaborating Centre for Drug Statistics Methodology (World Health Organization, 2021), Medline (2021), The Merck Index (2021), the European Public Assessment Reports (European Medicines Agency, 2021b) and the European Database on Food Additives (European Commission, 2021b).

Table 1 shows a list of ingredients that are traditionally not considered as medicine but used as food additives or supplements (such as amino-acids and vitamins) or hormones, and which became expensive branded products through a registry procedure with the EMA. Repurposed or repositioned drugs are also used in the treatment of rare diseases (drug repurposing is the discovery of a new use for already approved or investigational medicinal products). We have left these repositioned ingredients out of this table as they were initially intended for medical use after extensive medical research and only got a second life in rare diseases (Tambuyzer et al., 2020; Picavet et al., 2011). We have focused on traditionally ‘non-medical’ ingredients (“ingredient” in Table 1) used in the prevention, diagnosis and treatment of rare diseases that were discovered many years ago (“preparation” in Table 1), gained proven clinical benefit in the open medical literature (“evidence” in Table 1) and obtained a marketing authorization by EMA (“Marketing” in Table 1) on the basis of historical data and a limited number of clinical trials (“#Trial P” in Table 1). Several of these ingredients are allowed today as food additives or supplements (“Food” in Table 1). Ingredients

---

¹https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition
without a Drug Name (NA in Table 1) are compounded by pharmacists and are not marketed (yet) in the EU.

### DISCUSSION: COMMONS IN RELATION TO OPEN SCIENCE

As indicated in the first section, there are many debates going on about IP rights and alternative innovation and/or ownership models. Pleas are made to apply the principles of open science (in analogy to open software) in drug research and development. We support such pleas but we also wish to draw attention to a practice that runs parallel to the processes of industrial drug discovery and development. This practice is that of pharmaceutical compounding, where pharmacists make custom medicinal formulations to fit the needs of their patients, based on shared clinical experience, often using substances that are, strictly speaking, not even “drugs” but food additives or supplements. One angle to look at this practice is to consider it a special case of “open science”. Yet, open science is mostly used to discuss industrial drug development and innovation pathways. The case of pharmaceutical compounding with common food ingredients (additives or supplements) is not the same kind of innovation, nor the same kind of science. The relation between a community of professionals using common ingredients can be more adequately described with the historical and political notion of “the commons”. In modern times the commons were the common and natural resources accessible to all members of a society, held in common but not owned privately and managed for individual or collective benefit. Collective systems of managing common land in late medieval England is a well-known example. In the 16–18th Centuries, policies of “enclosure” gradually placed these collectively owned and exploited lands in private hands. These policies were later applied at a global scale. Posthoc rationalizations of these policies are based on the idea that the commons are untenable, because abuse and overexploitation will occur at some point (Hardin, 1968). This thesis has been disproven, and many examples of successful ‘commons’ have been analyzed by Nobel-prize winning economist Elinor Ostrom (1990). Today, there is a resurgence of the commons in areas ranging from open software to common urban spaces and the reclaiming of rights by indigenous peoples (Gutwirth, 2018). We argue in this paper that an important number of pharmaceutical ingredients should be conceived of and regulated as commons.

All of the ingredients in Table 1 were discovered many years ago (between 1868 and 1976) and gained proven clinical evidence (through experience and serendipity) for a rare disease in the open medical literature (between 1978 and 2013) before their marketing by a private sponsor as an “orphan drug”. These ingredients can be considered as res publicae or commons without any reason for market protection on the basis of historical data and a limited number of clinical trials. All the ingredients in Table 1 obtained clinical evidence in the open medical literature but got market access with incentives that did not encourage basic innovative research but rather (ab)used it.

The advantage of referring to the notion of the commons is a change in perspective—another way of approaching a particular existing practice that is driven by a different rationale than that of ‘sharing’ for the sake of innovation. An approach in terms of commons and “commoning” (as an activity) provides a better sociological description of practices of pharmaceutical

| Ingredient     | Drug Name       | Rare Disease                      | Daily Dose | Preparation | Evidence | Marketing | Food  | #Trial P |
|----------------|-----------------|-----------------------------------|------------|-------------|----------|-----------|-------|---------|
| Mannitol       | Bronchitol      | Cystic Fibrosis                   | 800 mg     | 1957        | 1978     | 2012      | *     | 642     |
| Betaine        | Cystadane       | Homocystinuria                    | 6,000 mg   | 1957        | 1981     | 2007      | *     |         |
| Cholic acid    | Kolbam          | Primary Bile acid deficiency      | 500 mg     | 1939        | 1990     | 2010      | *     | 52      |
| Cholic acid    | Orphacol        | Primary Bile acid deficiency      | 500 mg     | 1939        | 1990     | 2010      | *     |         |
| Zinc (Sulphate)| Wilzin          | Wilson’s Disease                  | 150 mg     | 1912        | 1992     | 2004      | —     |         |
| Bromelain      | Nexobrid        | Burn debridement                  | Ad Libitum | 1961        | 2010     | 2012      | —     | 156     |
| L-Carnitine    | LevoCarnit      | Congenital Urea cycle disorder    | 2,000 mg   | 1952        | 1997     | 2013      | —     |         |
| Folic acid     | Folavit         | Prevention Spina Bifida           | 4 mg       | 1947        | 1991     | 1997      | *     |         |
| Biotin         | Biotine         | Acylcoen A dehydrogen deficiency  | —          | 1976        | —        | NA        | *     |         |
| Cannabidiol    | Epidylox        | Lennox Gastaux Syndrome           | —          | 1964        | 2013     | 2019      | —     | 715     |
| Riboflavin     | Riboflavin      | Acylcoen A dehydrogen deficiency  | —          | 1935        | 2003     | NA        | *     |         |
| pThyroid Horm  | Natpar          | Hypoparathyroidism                | 0.1 mg     | —           | 1950     | 2017      | 124   |         |
| L-Citrulline   | N A             | CPS and OCT-deficiency            | 100 mg/kg  | 1938        | —        | NA        | —     |         |
| Creatine       | N A             | GAMT-deficiency                   | —          | 1968        | 2002     | NA        | —     |         |
| L-Cysteine     | N A             | —                                 | —          | 1926        | —        | NA        | *     |         |
| D-Mannose      | N A             | Congenital Deficiency Glycosylation | 600 mg/kg | 1941        | 1997     | NA        | —     |         |
| D-Ribose       | N A             | AMP-deaminase deficiency          | —          | 1909        | 1991     | NA        | —     |         |
| Glycine        | N A             | Diagnostic                        | 100 mg/kg  | 1924        | —        | NA        | *     |         |
| Uridine        | N A             | Pyrimidine pathway deficiency     | —          | 1931        | —        | NA        | —     |         |
| Beta-carotene  | N A             | Erythropoietische Protoporphyria  | 300 mg     | 1950        | 1980     | NA        | *     |         |
| Coenzyme Q 10  | N A             | Mitochondrial defects             | —          | 1979        | —        | NA        | —     |         |
| L-Arginine     | N A             | Congenital Urea cycle disorder    | —          | 1943        | 1989     | NA        | —     |         |
| Magnesium salts| NA              | Gitelman syndrome                | —          | NA          | 2008     | NA        | —     |         |
compounding. A sociological description is important, because it allows emphasizing specificities of compounding that remain unnoticed and unexploited in technical debates about drug discovery, development and systems of innovation.

A first specificity to be observed is the compound itself. In the case of food ingredients, pharmacists “repurpose” a substance that is not a drug. However, in certain patients, these ingredients have clinical effects. As with food allergies, where “harmless” ingredients provoke reactions that may be life-threatening, this shows that the boundary between food and drugs is often less clear in the clinic than in the realm of law (Hendrickx, 2019). While that legal boundary exists for good reasons (such as safety), legislation also leads to absurd situations where a common ingredient may change status and become more expensive because it is recognized as a drug for a specific rare disease. Food additives and supplements are the object of separate legislation for safety aspects but this legislation is unrelated to pharmaceuticals and medicine.

A second specificity is the community in which compounding takes place. Debates on open science and innovation tend to focus on R&D structures such as public-private partnerships and specific business models. We hereby overlook the know-how and practices that take place amongst pharmacists and doctors in clinical settings: the sharing of “recipes”, evidence and experience. While hospitals are also profit-seeking structures and subject to budgetary rationalization under national health and economic policies, the medical personnel and pharmacists have a primary interest in helping or curing patients. For rare diseases, medication tailored to a patient’s unique needs is often necessary and medical compounding is a form of what is called “point of care manufacturing” (though the term is today often reserved for the medical use of 3D printing). The hospital pharmacists gain no financial benefit from the practice of pharmaceutical compounding. The commitment to sharing recipes and keeping evidence-based records of treatments is not an innovation strategy, but a logical part of a common effort to help patients with rare disorders. In her famous analysis of case studies of contemporary practices in managing common lands and resources, economist Elinor Ostrom (1990) shows that a shared responsibility fuels the commitment of individuals and groups in managing their specific commons. She disproved the thesis that collective management sooner or later leads to abuse and overexploitation. If we consider the fact that pharmaceutical compounding is a practice of shared responsibility to make good use of commonly available ingredients, then this is indeed a practice of self-governing a “pharmaceutical commons”, as termed by Lezaun and Montgomery (2015) in a different context. This poses the question whether it would not be better to invest time and resources in establishing common databases (Dooms and Carvalho, 2018), methods, and recipes instead of evaluating private reformulations of these very same and common substances by the personnel of the EMA. Though not always reimbursed by public health authorities and social security, it is today perfectly legal to file applications for molecules that are part of a pharmaceutical commons, resulting in what can be called the “enclosure” of common therapies. If this were to be prohibited, then private companies would have to go and invest where their infrastructure and know-how are more useful—the development of new innovative molecular entity drugs—and this is a domain where the challenges of open science, innovation and alternative business models and partnerships merit our full attention indeed.

**CONCLUSION**

Regulatory agencies installed orphan drug regulations to stimulate research and development of new innovative treatments for life-threatening diseases with a low prevalence (rare diseases). We established a list of well-known food-related ingredients with clinical evidence for rare diseases in the open medical literature that obtained marketing authorization as an expensive “orphan drug”, protected by intellectual property (IP) rights. We have argued that these ingredients are part of an established practice of medicinal compounding and should be considered as “pharmaceutical commons”, and that regulatory incentives for private companies and market protection mechanisms such as IP rights are not justified in this case. In addition, the concept of the commons brings to light the practice of medicinal compounding—a form of point of care manufacturing - which is not profit-driven, but done by a skilled community of pharmacists with proper resources and evidence-bases who seek to cure patients with rare diseases. This is often overlooked in debates about open science and innovation and it provides a welcome opportunity to shift technocratic debates about IP, regulatory incentives and innovation models to the knowledge, expertise and resources that exist within pharmaceutical communities in the face of rare diseases.

**AUTHOR CONTRIBUTIONS**

KH conceptualized the main arguments and structure of the paper. MD did research into the databases and compiled Table 1. KH and MD both contributed to writing the paper and both authors approved of the submitted version.

**FUNDING**

KH benefitted, during the writing of the manuscript, from a postdoctoral research grant as a Senior Postdoc Fellow of the Research Foundation—Flanders (FWO). Grant number: 12S5820N

**ACKNOWLEDGMENTS**

Gratitude to the researchers of the Life Sciences and Society Lab of the KU Leuven for their most fruitful discussions.
REFERENCES

Bountra, C., Lee, W. H., and Lezaun, J. (2017). A New Pharmaceutical Commons: Transforming Drug Discovery. Oxford: Oxford Martin Policy Paper, 1–28.

Davies, E. H., Fulton, E., Brook, D., and Hughes, D. A. (2017). Affordable Orphan Drugs: a Role for Not-for-profit Organizations. Br. J. Clin. Pharmacol. 83, 1595–1601. doi:10.1111/bcp.13240

Dooms, M., and Carvalho, M. (2018). Compounded Medication for Patients with Rare Diseases. Orphanet J. Rare Dis. 13, 1. doi:10.1186/s13023-017-0741-y

Dooms, M., Pincé, H., and Simoens, S. (2013). Do we Need Authorized Orphan Drugs when Compounded Medications Are Available? J. Clin. Pharm. Ther. 38, 1–2. doi:10.1111/jcpt.12006

European Commission (2021a). Public Health - Union Register of Medicinal Products. Available at: https://ec.europa.eu/health/documents/community-register/html/index_en.htm (Accessed July, 2021)

European Commission (2021b). European Public Assessment Report. Available at: https://www.ema.europa.eu/en/glossary/european-public-assessment-report (Accessed July, 2021)

European Medicines Agency (2021a). Orphan Designation: Overview. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview (Accessed August, 2021)

European Medicines Agency (2021b). European Public Assessment Report. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview (Accessed August, 2021)

Gutwirth, S. (2018). Quel(s) Droit(s) Pour Quel(s) Commun(s) ?. Revue Interdisciplinaire d’Études Juridiques 81, 83–107. doi:10.3917/riej.081.0083

Hendrickx, K. (2019). The Political Space between Words and Things: Health Claims as Referential Displacement. Sci. as Cult. 28 (4), 427–448. doi:10.1080/09505431.2018.1557629

Huyard, C. (2009). How Did Uncommon Disorders Become ‘rare’ Diseases? History of a Boundary Object. Social. Health Illn 31 (4), 463–477. doi:10.1080/0140186080201143.x

Lezaun, J., and Montgomery, C. M. (2015). The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development. Sci. Technol. Hum. Values 40 (1), 3–29. doi:10.1177/016224391452349

Mikami, K. (2017). Orphans in the Market: the History of Orphan Drug Policy. Sociol. Sci. Technol. 32 (3), 609–630. doi:10.1093/shm/hkx098

Ostrom, E. (1990). Governing the Commons. The Evolution of Institutions for Collective Action. Cambridge: Cambridge University Press.

Picavet, E., Dooms, M., Cassiman, D., and Simoens, S. (2011). Drugs for Rare Diseases: Influence of Orphan Designation Status on price. Appl. Health Econ. Health Pol. 9 (4), 275–279. doi:10.2165/11590170-000000000-00000

Rubinstein, Y. R., Robinson, P. N., Gahl, W. A., Avillach, P., Baynam, G., Cederroth, H., et al. (2020). The Case for Open Science: Rare Diseases. JAMIA Open 3, 472–486. doi:10.1093/jamiaopen/ooaa030

Simoens, S., Cassiman, D., Picavet, E., and Dooms, M. (2011). Are Some Orphan Drugs for Rare Diseases Too Expensive? A Study of purchase versus Compounding Costs. Drugs Ther. Perspect. 27, 24–26. doi:10.2165/11601640-000000000-00000

Tambuyzer, E., Vandenendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., et al. (2020). Therapies for Rare Diseases: Therapeutic Modalities, Progress and Challenges Ahead. Nat. Rev. Drug Discov. 19 (2), 93–111. doi:10.1038/s41573-019-0049-9

The Merck Index (2021). The Merck Index* Online. Available at: https://www.rsc.org/merck-index

World Health Organization (2021). ATC/DDD Index. Available at: https://whocc.no/atc_ddd_index/(Accessed July, 2021)

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hendrickx and Dooms. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.